Related references
Note: Only part of the references are listed.Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis
Marlon Perera et al.
EUROPEAN UROLOGY (2020)
Prospective Evaluation of 18F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer in an Academic Center: A Focus on Disease Localization and Changes in Management
Hong Song et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
Impact of 68Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study
Ida Sonni et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study
Michael S. Hofman et al.
LANCET (2020)
68Ga-PSMA-11 PET/CT in Primary and Recurrent Prostate Carcinoma: Implications for Radiotherapeutic Management in 121 Patients
Stefan A. Koerber et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial
Wolfgang P. Fendler et al.
JAMA ONCOLOGY (2019)
Early lesion detection with 18F-DCFPyL PET/CT in 248 patients with biochemically recurrent prostate cancer
M. Wondergem et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
Metaanalysis of 68Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by Histopathology
Thomas A. Hope et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
68Gallium-labelled PSMA-PET/CT as a diagnostic and clinical decision-making tool in Asian prostate cancer patients following prostatectomy
Janice S. H. Tan et al.
CANCER BIOLOGY & MEDICINE (2019)
Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence
Jeremie Calais et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT
Matthias Eiber et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
Clinical impact of 68Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach
Simone Albisinni et al.
BJU INTERNATIONAL (2017)
68Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients
Florian Sterzing et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2016)
Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations
Sander Greenland et al.
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2016)
An improved synthesis of the radiolabeled prostate-specific membrane antigen inhibitor, [18F]DCFPyL
Hayden T. Ravert et al.
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS (2016)
Automated synthesis of [18F]DCFPyL via direct radiofluorination and validation in preclinical prostate cancer models
Vincent Bouvet et al.
EJNMMI RESEARCH (2016)
Prospective Comparison of F-18-Fluoromethylcholine Versus Ga-68-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy
Joshua J. Morigi et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Natural history of surgically treated high-risk prostate cancer
Alberto Briganti et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2015)
2-(3-{1-Carboxy-5-[(6-[18F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [18F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate Cancer
Ying Chen et al.
CLINICAL CANCER RESEARCH (2011)
Use of different definitions of biochemical failure after external beam radiotherapy changes conclusions about relative treatment efficacy for localized prostate cancer
Patrick A. Kupelian et al.
UROLOGY (2006)
Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference
Mack Roach et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2006)
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy
SJ Freedland et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: Long-term results
KA Roehl et al.
JOURNAL OF UROLOGY (2004)
Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: Continued rise of biochemical failure after 5 years
CL Amling et al.
JOURNAL OF UROLOGY (2000)
Share Paper
